Kidney cancer affects over 80,000 Americans annually, with renal cell carcinoma as the dominant type. Benjamin R. Lee, MD, MBA, outlines current AUA guideline recommendations, including when to…
Dr. Allison Betof Warner from Stanford University joins Rahul Gosain, MD and Rohit Gosain, MD, on the Oncology Brothers podcast to discuss melanoma treatment. The conversation covers the…
NEW YORK (Reuters Health) – Response rates are higher when bortezomib plus dexamethasone rather than vincristine plus doxorubicin plus dexamethasone (VAD) is used as induction therapy before stem-cell…
NEW YORK (Reuters Health) – Men whose baseline PSA is less than 2.0 ng/mL are unlikely to benefit from further screening for prostate cancer, according to findings reported…
NEW YORK (Reuters Health) – A finding of homozygosity for mutations that cause Gaucher disease in patients who report no symptoms of the disorder warrants further followup. Manifestations…
NEW YORK (Reuters Health) – HER2 protein and gene expression predict the response of breast cancer patients to adjuvant trastuzumab therapy, but which test provides the best information?…
NEW YORK (Reuters Health) – Rates of clearance of high-grade anal canal intraepithelial neoplasia in men with HIV are improved considerably by topical application of imiquimod cream, a…
NEW YORK (Reuters Health) – Men undergoing androgen deprivation therapy for prostate cancer halve their risk of vertebral fractures if they take the selective estrogen receptor modulator toremifene…
NEW YORK (Reuters Health) – A Canadian study has identified several readily available clinical factors that help determine the risk of fractures in men with prostate cancer undergoing…
NEW YORK (Reuters Health) – Among adult patients being treated for hematologic malignancies and who are at high risk for tumor lysis syndrome with hyperuricemia, intravenous rasburicase does…
NEW YORK (Reuters Health) – Women with a finding of atypical glandular cells (AGC) on cervical cytology are more likely than those without AGC to have malignant breast…
NEW YORK (Reuters Health) – After induction chemoimmunotherapy in previously untreated symptomatic patients with chronic lymphocytic leukemia (CLL), consolidation therapy with the monoclonal anti-CD52 antibody alemtuzumab (Campath-1H) improved…
